Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 3
1998 3
2000 1
2003 2
2004 1
2005 4
2006 3
2007 4
2008 4
2009 5
2010 7
2011 7
2012 8
2013 13
2014 9
2015 5
2016 13
2017 12
2018 10
2019 4
2020 10
2021 11
2022 11
2023 8
2024 9
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I.
Combarel D, Dousset L, Bouchet S, Ferrer F, Tetu P, Lebbe C, Ciccolini J, Meyer N, Paci A. Combarel D, et al. Among authors: bouchet s. Crit Rev Oncol Hematol. 2024 Jul;199:104384. doi: 10.1016/j.critrevonc.2024.104384. Epub 2024 May 16. Crit Rev Oncol Hematol. 2024. PMID: 38762217 Review.
Mercury Reduction by Nanoparticulate Vivianite.
Etique M, Bouchet S, Byrne JM, ThomasArrigo LK, Kaegi R, Kretzschmar R. Etique M, et al. Among authors: bouchet s. Environ Sci Technol. 2021 Mar 2;55(5):3399-3407. doi: 10.1021/acs.est.0c05203. Epub 2021 Feb 8. Environ Sci Technol. 2021. PMID: 33554594 Free PMC article.
Comment on: Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV.
Benaboud S, Solas C, Bouchet S, Gregoire M, Lemaitre F, Venisse N, Lê MP, Muret P, Parant F, Neant N, Boujafaar S, Lagoutte-Renosi J, Garraffo R, Peytavin G. Benaboud S, et al. Among authors: bouchet s. J Antimicrob Chemother. 2023 Mar 2;78(3):853-854. doi: 10.1093/jac/dkad009. J Antimicrob Chemother. 2023. PMID: 36683308 No abstract available.
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part II.
Ferrer F, Tetu P, Dousset L, Lebbe C, Ciccolini J, Combarel D, Meyer N, Paci A, Bouchet S. Ferrer F, et al. Among authors: bouchet s. Crit Rev Oncol Hematol. 2024 Aug;200:104385. doi: 10.1016/j.critrevonc.2024.104385. Epub 2024 May 27. Crit Rev Oncol Hematol. 2024. PMID: 38810843 Review.
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F; French CML Group (FiLMC). Roy L, et al. Among authors: bouchet s. Br J Haematol. 2023 Jan;200(2):175-186. doi: 10.1111/bjh.18486. Epub 2022 Oct 10. Br J Haematol. 2023. PMID: 36214090 Clinical Trial.
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
Venisse N, Peytavin G, Bouchet S, Gagnieu MC, Garraffo R, Guilhaumou R, Solas C; ANRS-AC43 Clinical Pharmacology Committee, SFPT Therapeutic Drug Monitoring and Treatment Personalization group. Venisse N, et al. Among authors: bouchet s. Antiviral Res. 2020 Sep;181:104866. doi: 10.1016/j.antiviral.2020.104866. Epub 2020 Jul 10. Antiviral Res. 2020. PMID: 32659293 Free PMC article. Review.
150 results